Eton Pharmaceuticals, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Eton Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $394.00K, a 5528.57% increase year-over-year.
- Eton Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $0.00.
- Eton Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-03-31 was $7.00K, a 94.70% decline year-over-year.
- Eton Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2023-06-30 was $0.00.
- Eton Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $35.00K, a 89.68% decline from fiscal 2021.
- Eton Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $339.00K, a 32.94% increase from fiscal 2020.
- Eton Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2020 was $255.00K, a 19.16% increase from fiscal 2019.
- Eton Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2019 was $214.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2025-03-31 | $394.00K 10-Q · filed 2025-05-13 | |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $7.00K 10-Q · filed 2025-05-13 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $167.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $132.00K 10-Q · filed 2024-05-09 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $35.00K 10-K · filed 2024-03-14 |
| 2022-09-30 | $35.00K 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $339.00K 10-K · filed 2024-03-14 |
| 2021-09-30 | $9.00K 10-Q · filed 2022-11-10 | $454.00K derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-06-30 | $227.00K 10-Q · filed 2022-08-11 | $488.00K derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | $103.00K 10-Q · filed 2022-05-12 | $327.00K derived: sum of 4 quarters · filed 2023-03-16 |
| 2020-12-31 | $115.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $255.00K 10-K · filed 2023-03-16 |
| 2020-09-30 | $43.00K 10-Q · filed 2021-11-16 | $200.00K derived: sum of 4 quarters · filed 2022-03-16 |
| 2020-06-30 | $66.00K 10-Q · filed 2021-08-16 | $234.00K derived: sum of 4 quarters · filed 2022-03-16 |
| 2020-03-31 | $31.00K 10-Q · filed 2021-05-13 | $241.00K derived: sum of 4 quarters · filed 2022-03-16 |
| 2019-12-31 | $60.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $214.00K 10-K · filed 2022-03-16 |
| 2019-09-30 | $77.00K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $73.00K 10-Q · filed 2020-08-12 | |
| 2019-03-31 | $4.00K 10-Q · filed 2020-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |